Harvard Law School, J.D.
  • Harvard Environmental Law Review, Article and Technical Editor
Yale University, B.S.
  • Molecular, Cellular, and Developmental Biology
Inter-University Center for Japanese Language Studies
  • 10-month program


Court Admissions

News & Resources


Cristina Almendarez is an intellectual property litigation attorney whose practice includes patent, trademark, and copyright litigation. Cristina focuses her practice on patent infringement covering a range of technology, products, and industries. Her experience includes representing clients across a range of products and technologies, including biologic and pharmaceutical drugs, automotive parts, consumer goods, and food processing and packaging machinery. Cristina has also represented and advised several clients in federal litigation actions for trade dress infringement, false advertising, unfair competition, misappropriation of trade secrets, and breach of contract matters. Prior to law school, Cristina completed the Inter-University Center for Japanese Language Studies’s 10-month program in Yokohama.

Cristina has worked on issues across various phases of litigation, including pre-suit analysis and strategy, discovery and depositions, claim construction, summary judgment, and appeal. Her past work also includes coordination between parallel district court litigation and USPTO inter partes review proceedings.


Representative Matters

Cristina has litigated significant life sciences-related cases, including, for example:

  • Represents named inventors of an extensive cardiac stent patent portfolio in litigation in federal court regarding breach of contract for royalties. The case is being litigated similar to a patent infringement case including the exchange of infringement and invalidity contentions, and involves a parallel inter partes review proceeding.
  • Represented Hospira, Inc., a subsidiary of Pfizer, Inc., Celltrion, Inc. and Celltrion Healthcare Co., Ltd. adverse to Janssen Biotech, Inc. in litigation in federal court related to a biosimilar version of Janssen’s multi-billion dollar drug Remicade®. The case involved the first biosimilar monoclonal antibody to be approved by the FDA, and is one of the earliest cases filed under the Biologics Price Competition and Innovation Act (BPCIA).
  • Assisted with appeals of two highly publicized motions for summary judgment that invalidated Janssen’s patent related to the infliximab antibody. The district court litigation ended with a second win in the form of a judgment of non-infringement related to the second patent asserted in the case.
  • Represented Sandoz Inc. in a patent litigation regarding a biosimilar version of Amgen’s drug Neulasta®. The litigation was successfully terminated when Sandoz obtained an order dismissing Amgen’s related declaratory judgment.

Trademark, Copyright, Patent, Trade Secret and False Advertising 

  • Represented Dyson, Inc. in false advertising litigations with SharkNinja Operating LLC related carpet cleaning superiority advertising claims and suction performance claims.
  • Represented IMA S.p.A. and Fillshape S.r.l in a trade secret misappropriation and patent infringement case relating to food pouch manufacturing. Obtained dismissal of the claims and a stipulated to transfer of the case to an alternative forum, after which the case was resolved by favorable settlement.

Prior Experience

  • Kirkland & Ellis, Associate, 2014-2018
    American Civil Liberties Union of Illinois, PILI Fellow, 2014
    U.S. Attorney’s Office – W.D. Washington, Summer Law Clerk, 2012


  • Japanese (Intermediate)
  • Spanish (Conversational)


Professional & Community Involvement

American Bar Association

Harvard Law Society of Illinois

News & Resources


Press Releases